KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.

Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Tom Waddell, Dmitry Nosov, Frédéric Pouliot, Boris Alekseev, Denis Soulières, Bohuslav Melichar, Ihor Vynnychenko, Sergio Jobim de Azevedo, Delphine Borchiellini, Raymond S McDermott, Jens Bedke, Satoshi Tamada, Sterling Wu, Julia Markensohn, Yiwei Zhang, Andrey Loboda, Amir Vajdi, Rodolfo F Perini, Joseph Burgents, Thomas Powles

Nat Med 31(10) 3475-3484

PMID40750932
PMCIDPMC12532709
DOI10.1038/s41591-025-03867-5
发表日期2025-08-01
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

At the first interim analysis of the phase 3 KEYNOTE-426 trial, first-line pembrolizumab plus axitinib showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) over sunitinib for advanced renal cell carcinoma (RCC). To assess long-term durability of clinical outcomes and elucidate predictive biomarkers for RCC, we performed efficacy and prespecified exploratory biomarker analyses from KEYNOTE-426 with ≥5 years of follow-up. Pembrolizumab plus axitinib showed sustained benefits in OS (hazard ratio: 0.84; 95% confidence interval: 0.71-0.99), PFS (hazard ratio: 0.69; 95% confidence interval: 0.59-0.81) and ORR (60.6% versus 39.6%) compared to sunitinib. An 18-gene T-cell-inflamed gene expression profile (TcellinfGEP) was positively associated with OS (P = 0.002), PFS (P < 0.0001) and ORR (P < 0.0001) within the pembrolizumab plus axitinib arm. An angiogenesis signature was positively associated with OS (P = 0.004) within the pembrolizumab plus axitinib arm and with OS (P < 0.0001), PFS (P < 0.001) and ORR (P = 0.002) within the sunitinib arm. Across arms, programmed cell death ligand 1 combined positive score was only associated (negatively) with OS within the sunitinib arm (P = 0.025). Additionally, PBRM1 (polybromo-1) mutation had a positive association with ORR (P = 0.002) within the pembrolizumab plus axitinib arm. Within the sunitinib arm, OS was positively associated with VHL (von Hippel-Lindau tumor suppressor gene) (P = 0.040) and PBRM1 (P = 0.010) mutations and was negatively associated with BAP1 (BRCA1-associated protein 1) mutation (P = 0.019). Results showed a sustained clinical benefit with pembrolizumab plus axitinib over sunitinib and provide valuable information on biomarkers for immunotherapy-based treatment combinations in advanced RCC. Prospective clinical investigations are needed for biomarker-directed treatment for advanced RCC. ClinicalTrials.gov identifier: NCT02853331 .

KM 提取结果

6 个 Figure · 27 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 2

Fig. 2. OS, PFS and DOR in the intention-to-treat population. a , Kaplan–Meier estimates of OS. b , Kaplan–Meier estimates of PFS. c , OS by subgroups. d , PFS by subgroups. e , Kaplan–Meier estimates of DOR in participants with a confirmed objective response. In a , b and e , tick marks represent censored data. In c and d , shaded squares correspond to the hazard ratios (HRs), and the error bars (horizontal lines) correspond to the 95% confidence intervals (CIs).

A

OS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

DOR

Fig. 2 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure8 个面板

Fig. 4

Fig. 4. Kaplan–Meier estimates of survival by Tcell inf GEP or angiogenesis signature cutoff. a , OS by Tcell inf GEP cutoff. b , PFS by Tcell inf GEP cutoff. c , OS by angiogenesis signature cutoff. d , PFS by angiogenesis signature cutoff. Tick marks represent censored data. CI, confidence interval; HR, hazard ratio.

A

OS

Fig. 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

OS

Fig. 4 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Fig. 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_4

PFS

Fig. 4 · Panel B_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B_4 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

Fig. 4 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 2:short span
查看结果
C_6

OS

Fig. 4 · Panel C_6

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C_6 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme jump曲线 1:extreme upward reversal
查看结果
D

PFS

Fig. 4 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D_8

PFS

Fig. 4 · Panel D_8

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D_8 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Extended Data Fig. 4

Extended Data Fig. 4. Kaplan-Meier estimates of survival by VHL mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using a Cox proportional hazards model, with adjustment for IMDC risk category. Tick marks represent censored data. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; VHL , von Lindau-Hippel tumor suppressor gene; WT, wild type.

A

overall survival

Extended Data Fig. 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

overall survival

Extended Data Fig. 4 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

progression-free survival

Extended Data Fig. 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_4

progression-free survival

Extended Data Fig. 4 · Panel B_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B_4 是同一 Extended Data Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
KM Figure4 个面板

Extended Data Fig. 5

Extended Data Fig. 5. Kaplan-Meier estimates of survival by PBRM1 mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NE, not evaluable; OS, overall survival; PBRM1 , polybromo-1 gene; PFS, progression-free survival; WT, wild type.

A

Overall survival

Extended Data Fig. 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

Overall survival

Extended Data Fig. 5 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Extended Data Fig. 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_4

Progression-free survival

Extended Data Fig. 5 · Panel B_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B_4 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Extended Data Fig. 6

Extended Data Fig. 6. Kaplan-Meier estimates of survival by SETD2 mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; SETD2 , SET domain containing 2, histone lysine methyltransferase gene; WT, wild type.

A

Overall survival

Extended Data Fig. 6 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

Overall survival

Extended Data Fig. 6 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Extended Data Fig. 6 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_4

Progression-free survival

Extended Data Fig. 6 · Panel B_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B_4 是同一 Extended Data Fig. 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Extended Data Fig. 7

Extended Data Fig. 7. Kaplan-Meier estimates of survival by BAP1 mutational status. a , Overall survival. b , Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. BAP1 , BRCA1 -associated protein 1 gene; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; WT, wild type.

A

Overall survival

Extended Data Fig. 7 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

Overall survival

Extended Data Fig. 7 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Extended Data Fig. 7 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
B_4

Progression-free survival

Extended Data Fig. 7 · Panel B_4

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B_4 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. CONSORT diagram. a Completed pembrolizumab treatment after discontinuing axitinib.
非 KM Figure
Fig. 3Fig. 3. Participant-level distribution of select biomarker scores by response status and treatment arm. a , Tcell inf GEP (pembrolizumab plus axitinib, n = 369; sunitinib, n = 361). b , Angiogenesis signature (pembrolizumab plus axitinib, n = 369; sunitinib, n = 361). c , PD-L1 CPS (pembrolizumab plus axitinib, n = 407; sunitinib, n = 409). The center line corresponds to the median, and the box is delineated by the first and third quartiles. Whiskers extend to any points within 1.5 times the interquartile range, with points lying beyond identified individually as potential outliers. P values are nominal (one-sided for pembrolizumab plus axitinib and two-sided for sunitinib) and were derived using a logistic regression model, with adjustment for IMDC risk category. Significance was prespecified at α = 0.05.
非 KM Figure
Extended Data Fig. 1Extended Data Fig. 1. Correlogram plot of PD-L1 CPS, RNA sequencing signatures, and single genes. CPS, combined positive score; EMT, epithelial-to-mesenchymal transition; gMDSC, granulocytic myeloid-derived suppressor cell; mMDSC, monocytic myeloid-derived suppressor cell; PD-L1, programmed cell death ligand 1; Tcell inf GEP, T-cell–inflamed gene expression profile; TGF-β, transforming growth factor β.
非 KM Figure
Extended Data Fig. 2Extended Data Fig. 2. Clustering and distribution of molecular subtypes. a , Molecular subtype clustering. b , Distribution by IMDC risk categories. c , Distribution by tumor PD-L1 CPS. Molecular subtypes are based on transcriptomically defined clustering patterns identified in the IMmotion151 phase 3 study. “Other” includes samples that could not be assigned to the angiogenic/stromal, angiogenic, immune/proliferative, proliferative, or stromal/proliferative subtype. CPS, combined positive score; EMT, epithelial-to-mesenchymal transition; gMDSC, granulocytic myeloid-derived suppressor cell; HIF-2α, hypoxia-inducible factor- α; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; mMDSC, monocytic myeloid-derived suppressor cell; PD-L1, programmed cell death ligand 1; Tcell inf GEP, T-cell–inflamed gene expression profile; TGF-β, transforming growth factor β.
非 KM Figure
Extended Data Fig. 3Extended Data Fig. 3. ORR by molecular subtypes and mutational status. a , ORR per transcriptomically defined clustering pattern identified in the IMmotion151 phase 3 study (pembrolizumab plus axitinib, n = 369; sunitinib, n = 361). b , ORR by mutational status in the pembrolizumab plus axitinib arm ( n = 347). c , ORR by mutational status in the sunitinib arm ( n = 351). In panel a , “Other” includes samples that could not be assigned to angiogenic/stromal, angiogenic, immune/proliferative, proliferative, or stromal/proliferative subtype. In panels a-c , bars represent ORR, derived by dividing the number of participants with a complete or partial response by the total number of patients in that subgroup, multiplied by 100. Error bars indicate 95% confidence intervals. P values shown in panels b and c are multiplicity-adjusted (one-sided for pembrolizumab plus axitinib and two-sided for sunitinib) and were derived using logistic regression model, with adjustment for IMDC risk category. Significance was prespecified at α = 0.10. BAP1 , BRCA1 -associated protein 1 gene; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NS, not significant; ORR, objective response rate; PBRM1 , polybromo-1 gene; SETD2 , SET domain containing 2, histone lysine methyltransferase gene; VHL , von Lindau-Hippel tumor suppressor gene.
非 KM Figure